{"id":5744,"date":"2024-08-08T06:34:26","date_gmt":"2024-08-08T11:34:26","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5744"},"modified":"2025-06-27T11:15:09","modified_gmt":"2025-06-27T16:15:09","slug":"nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en la cuarta conferencia virtual anual de oftalmolog\u00eda de HC Wainwright"},"content":{"rendered":"
\n
\n
\n

<\/h1>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>, Texas\u2014 8 de agosto de 2024<\/span><\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en fase avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy que\u00a0Sulagna Bhattacharya<\/span>, Director General y\u00a0Samarendra Mohanty<\/span>, presidente de Nanoscope Therapeutics, presentar\u00e1 y participar\u00e1 en una mesa redonda en el\u00a02024 HC Wainwright 4th<\/sup>\u00a0Conferencia Virtual Anual de Oftalmolog\u00eda<\/a>, teniendo lugar el\u00a015 de agosto de 2024<\/span>.<\/p>\n

Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n

Tipo de sesi\u00f3n:\u00a0<\/b>Presentaci\u00f3n
Fecha de la sesi\u00f3n:<\/b>\u00a0Jueves 15 de agosto<\/span>
Tiempo de sesi\u00f3n:<\/b>\u00a07:00 a.m. hora del Este<\/span>
Presentadores:<\/b>\u00a0Sulagna Bhattacharya<\/span>, Director General y\u00a0Samarendra Mohanty<\/span>, Doctorado, Presidente<\/p>\n

La Sra. Bhattacharya y el Dr. Mohanty brindar\u00e1n una actualizaci\u00f3n corporativa sobre las pr\u00f3ximas actividades de Nanoscope luego de los datos positivos de fin de estudio del ensayo cl\u00ednico aleatorizado de la compa\u00f1\u00eda de MCO-010 en pacientes con retinitis pigmentosa (RP) y el ensayo de fase 2 en Enfermedad de Stargardt. La presentaci\u00f3n tambi\u00e9n presentar\u00e1 la plataforma de administraci\u00f3n de l\u00e1ser MCO-020 de pr\u00f3xima generaci\u00f3n para la terapia g\u00e9nica no viral de atrofias geogr\u00e1ficas (GA) secundarias a la DMAE. A esto le seguir\u00e1 una mesa redonda sobre programas cl\u00ednicos avanzados dirigidos a indicaciones retinianas moderada por Yi Chen, PhD, director general de Equity Research en HC Wainright. Los detalles del panel son los siguientes:<\/p>\n

T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Candidatos en etapa tard\u00eda sin riesgo para trastornos de la retina
Tipo de sesi\u00f3n:<\/b>\u00a0Panel de discusi\u00f3n
Fecha de la sesi\u00f3n:\u00a0<\/b>Jueves 15 de agosto\u00a0
Tiempo de sesi\u00f3n:\u00a0<\/b>11:00 a. m. hora del Este<\/span>,
Miembro del jurado:\u00a0<\/b>Samarendra Mohanty<\/span>, Doctorado, Presidente<\/p>\n

Los panelistas discutir\u00e1n los caminos que han forjado para sus respectivos programas hacia un estado cl\u00ednico avanzado. Esto incluir\u00e1 informaci\u00f3n sobre la navegaci\u00f3n de la econom\u00eda de fabricaci\u00f3n, regulatoria y de salud en el camino hacia la aprobaci\u00f3n y el lanzamiento comercial.<\/p>\n

Para registrarse para la transmisi\u00f3n web en vivo, comun\u00edquese con su representante de HC Wainwright. Una repetici\u00f3n del webcast estar\u00e1 disponible a trav\u00e9s de HC Wainwright por un tiempo limitado despu\u00e9s del evento.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010,\u00a0anunci\u00f3 recientemente los datos de 100 semanas de<\/a>\u00a0la fase de RESTAURACI\u00d3N\u00a02b<\/span>\/3 ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la GA secundaria a AMD.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS, TX — Aug. 8, 2024\u00a0 — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that\u00a0Sulagna Bhattacharya, Chief Executive Officer and\u00a0Samarendra Mohanty, President of Nanoscope Therapeutics, will present and participate in a panel discussion at the\u00a02024 H.C. Wainwright 4th\u00a0Annual Ophthalmology Virtual […]<\/p>\n","protected":false},"author":6,"featured_media":5746,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5744","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-08T11:34:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:15:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference\",\"datePublished\":\"2024-08-08T11:34:26+00:00\",\"dateModified\":\"2025-06-27T16:15:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\"},\"wordCount\":418,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/NSCOPE_LI_Wainwright2024rev2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/NSCOPE_LI_Wainwright2024rev2.jpg\",\"datePublished\":\"2024-08-08T11:34:26+00:00\",\"dateModified\":\"2025-06-27T16:15:09+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/NSCOPE_LI_Wainwright2024rev2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/NSCOPE_LI_Wainwright2024rev2.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 4.\u00aa Conferencia Virtual Anual de Oftalmolog\u00eda de HC Wainwright.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-08-08T11:34:26+00:00","article_modified_time":"2025-06-27T16:15:09+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference","datePublished":"2024-08-08T11:34:26+00:00","dateModified":"2025-06-27T16:15:09+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/"},"wordCount":418,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/08\/NSCOPE_LI_Wainwright2024rev2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","url":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","name":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 4.\u00aa Conferencia Virtual Anual de Oftalmolog\u00eda de HC Wainwright.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/08\/NSCOPE_LI_Wainwright2024rev2.jpg","datePublished":"2024-08-08T11:34:26+00:00","dateModified":"2025-06-27T16:15:09+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/08\/NSCOPE_LI_Wainwright2024rev2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/08\/NSCOPE_LI_Wainwright2024rev2.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5744"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5744\/revisions"}],"predecessor-version":[{"id":9040,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5744\/revisions\/9040"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5746"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}